611 related articles for article (PubMed ID: 8160561)
21. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
22. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
24. Allergen-specific immunotherapy with recombinant grass pollen allergens.
Jutel M; Jaeger L; Suck R; Meyer H; Fiebig H; Cromwell O
J Allergy Clin Immunol; 2005 Sep; 116(3):608-13. PubMed ID: 16159631
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
[TBL] [Abstract][Full Text] [Related]
27. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
28. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
[TBL] [Abstract][Full Text] [Related]
30. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen.
Marogna M; Spadolini I; Massolo A; Berra D; Zanon P; Chiodini E; Canonica GW; Passalacqua G
Ann Allergy Asthma Immunol; 2009 Jan; 102(1):69-75. PubMed ID: 19205289
[TBL] [Abstract][Full Text] [Related]
31. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy.
Van Overtvelt L; Baron-Bodo V; Horiot S; Moussu H; Ricarte C; Horak F; Zieglmayer P; Zieglmayer R; Montagut A; Galvain S; de Beaumont O; Le Gall M; Moingeon P
Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279
[TBL] [Abstract][Full Text] [Related]
32. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
33. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.
Stelmach I; Kaluzińska-Parzyszek I; Jerzynska J; Stelmach P; Stelmach W; Majak P
Allergy; 2012 Mar; 67(3):312-20. PubMed ID: 22142341
[TBL] [Abstract][Full Text] [Related]
34. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Kopp M; Liebke C; Lange J; Wahn U; Niggemann B
Int Arch Allergy Immunol; 2005 Feb; 136(2):134-41. PubMed ID: 15650310
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
36. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
[TBL] [Abstract][Full Text] [Related]
37. Effect of AIT in children including potential to prevent the development of asthma.
Valovirta E
Allergy; 2011 Jul; 66 Suppl 95():53-4. PubMed ID: 21668856
[TBL] [Abstract][Full Text] [Related]
38. Monoid sublingual immunotherapy.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
40. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.
Howarth P; Malling HJ; Molimard M; Devillier P
Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]